Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

daclizumab

A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-Tac
Anti-Tac Humanized Monoclonal Antibody
anti-Tac monoclonal antibody
Dacliximab
US brand name:Zenapax
Abbreviation:MOAB anti-Tac
IND number:2091
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search